WEST PHARMACEUTICAL SERVICES, INC.
Solutions for Injectable Drug Delivery NYSE:WST www.westpharma.com
© 2012 by West Pharmaceutical Services, Inc., Lionville, PA.
All rights reserved. This material is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any
form or by any means, electronic, mechanical, photocopying or otherwise, without written permission of West Pharmaceutical Services, Inc.. All
trademarks and registered trademarks are property of West Pharmaceutical Services, Inc., unless noted otherwise.
form or by any means, electronic, mechanical, photocopying or otherwise, without written permission of West Pharmaceutical Services, Inc.. All
trademarks and registered trademarks are property of West Pharmaceutical Services, Inc., unless noted otherwise.
CL King 10th Annual Best Ideas Conference
New York, NY
September 12, 2012
Safe Harbor Statement
Cautionary Statement Under the Private Securities Litigation Reform Act of 1995
This presentation and any accompanying management commentary contain “forward-looking statements”
as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to statements about expected financial results for 2012 and future years.
as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to statements about expected financial results for 2012 and future years.
Each of these estimates is based on preliminary information, and actual results could differ from these
preliminary estimates. We caution investors that the risk factors listed under “Cautionary Statement” in
our press releases, as well as those set forth under the caption "Risk Factors" in our most recent Annual
Report on Form 10-K as filed with the Securities and Exchange Commission and as revised or
supplemented by our quarterly reports on Form 10-Q, could cause our actual results to differ materially
from those estimated or predicted in the forward-looking statements. You should evaluate any statement
in light of these important factors. Except as required by law or regulation, we undertake no obligation to
publicly update any forward-looking statements, whether as a result of new information, future events, or
otherwise.
preliminary estimates. We caution investors that the risk factors listed under “Cautionary Statement” in
our press releases, as well as those set forth under the caption "Risk Factors" in our most recent Annual
Report on Form 10-K as filed with the Securities and Exchange Commission and as revised or
supplemented by our quarterly reports on Form 10-Q, could cause our actual results to differ materially
from those estimated or predicted in the forward-looking statements. You should evaluate any statement
in light of these important factors. Except as required by law or regulation, we undertake no obligation to
publicly update any forward-looking statements, whether as a result of new information, future events, or
otherwise.
Non-GAAP Financial Measures
Certain financial measures included in these presentation materials, and which may be referred to in
management’s discussion of the Company’s results and outlook, are Non-GAAP (Generally Accepted
Accounting Principles) financial measures. Please refer to the “Non-GAAP Financial Measures” and
“Notes to Non-GAAP Financial Measures” at the end of these materials for more information. Non-GAAP
financial measures should not be considered in isolation or as an alternative to such measures
determined in accordance with GAAP.
management’s discussion of the Company’s results and outlook, are Non-GAAP (Generally Accepted
Accounting Principles) financial measures. Please refer to the “Non-GAAP Financial Measures” and
“Notes to Non-GAAP Financial Measures” at the end of these materials for more information. Non-GAAP
financial measures should not be considered in isolation or as an alternative to such measures
determined in accordance with GAAP.
2
Pharmaceutical
Packaging Systems
Packaging Systems
Pharmaceutical
Delivery Systems
Delivery Systems
• A globally diverse manufacturer of
products used primarily in containing
and administering
small-volume parenteral drugs
products used primarily in containing
and administering
small-volume parenteral drugs
• Strong competitive position
§ Diversified customer base
§ Proprietary technology
§ Global footprint
§ Significant barriers to entry
• Stability with growth potential
§ Proprietary Products
§ Geographic Expansion
• Financial strength to invest
§ Reliable operating cash flow
§ Well capitalized
3
Who We Are
A Diverse, Stable Customer Base
(representative healthcare customers)
(representative healthcare customers)
PHARMACEUTICAL / BIOTECHNOLOGY
GENERIC
MEDICAL DEVICE
4
The West Transition
• Founded in Philadelphia (1923) and listed on NYSE since 1980
• Initiated strategic transformation in 2001 to become a leading global supplier
of value-added pharmaceutical packaging systems and components
of value-added pharmaceutical packaging systems and components
5
‘03 ‘04 ‘05 ‘06 ‘07 ‘08 ‘09 ‘10 ‘11
2001
$392 M
$392 M
2011
$1.2 B
$1.2 B
Kinston
recovery
Sale of
CCI
CCI
Sale of
Drug
Drug
Delivery
Acquired
Tech Group,
Medimop
Tech Group,
Medimop
Began
Eur/Asia
expansion
expansion
Acquired
Pharma
Pen
Pharma
Pen
Acquired
Normandy
Normandy
Acquired
LaModel
LaModel
China
plastics
completed
plastics
completed
Global
Quality
Initiative
Quality
Initiative
China
rubber
begun
rubber
begun
Business Segments
$857
$337
2011 Revenues
($ millions)
Delivery Systems
• Contract manufacturing base
• Multi-material
• Project management
• Automated assembly
• Regulated products
• Capabilities + IP = proprietary
delivery devices
delivery devices
• Proprietary devices are
expected to drive growth
expected to drive growth
Packaging Systems
• Established leadership
• Designed-in revenue base
• Diverse global capabilities
• High market shares
• Steady growth in base
• Increasing unit value of products
and geographic expansion are
expected to enhance growth
and geographic expansion are
expected to enhance growth
6
2012 Q2 Overview
•Second Quarter 2012 Sales Grew 5.5% (11.3% at constant
currency)
currency)
– High-value product growth and price were key components
– Backlog still growing: longer-lead times, customers building
inventories
inventories
•Pharmaceutical Packaging and Device markets:
– Customer’s new product pipelines showing signs of strength
– Patent cliff front and center
– Shift to large molecule products continues
– Global shift in product sourcing (e.g., India generic growth)
– More demanding regulatory environment
•Convertible Debenture Tender Offer Completed
7
Q2 Summary Results
$ millions, except per-share data
$ millions, except per-share data
(1) These are Non-GAAP measurements. For an explanation and reconciliation of these items, see “Cautionary Statement”
(Slide 2) and “Non-GAAP Financial Measures” and “Notes to Non-GAAP Financial Measures” (Slides 30 - 32).
(Slide 2) and “Non-GAAP Financial Measures” and “Notes to Non-GAAP Financial Measures” (Slides 30 - 32).
8
Selected Factors Expected to Impact
Second-Half 2012 and Comparisons
Second-Half 2012 and Comparisons
See “Cautionary Statement” on slide 2. This is not an exclusive list of risks.
• Stronger US dollar impact on reported sales, profits from
international operations vs. first half and prior year
international operations vs. first half and prior year
• Pricing changes vs. prior year smaller than first half 2012
• Normal seasonality: West and customer shutdowns for
summer and holiday season impact sales and production
efficiency vs. first half
summer and holiday season impact sales and production
efficiency vs. first half
• First-half sales that are not expected to recur:
– Production in response to drug shortages / regulatory constraints
– Customer new product launches
• Expectations for new products and development
9
What will drive growth?
– Growth in emerging markets – Escalating regulatory and quality demands – Adding plants: China, India – Expanding Westar® and Envision® capacity, introducing NovaPure® components | – Growth in combination products: • safety, dosing accuracy, ease of use • deliver cost savings • product differentiation – Daikyo Crystal Zenith® products: • Increasing awareness of glass quality issues – Delivery technology platforms: • SmartDose® electronic patch injector • ConfiDose® auto-injector – Reconstitution products – Safety syringes |
Daikyo Crystal Zenith® is a registered trademark of Daikyo Seiko, Ltd.
Packaging Systems
Delivery Systems
10
Category | Key Customers | Projected Growth |
Diabetes | > 10 % | |
Oncology | > 10 % | |
Vaccines | > 10 % | |
Autoimmune | > 8% | |
Generics | >10% |
IMS April 2010 Report; Business Insights 2009; GBI Research 2009
Therapeutic Category Growth Drivers
11
Packaging Segment Overview
2011 Revenue
($ millions)
Packaging Systems
• Market leader
• Strong recurring revenue base
• Global manufacturing
• Steady growth in base
• Future growth will be driven by:
added value per unit sold;
geographic expansion; and
growth in key therapeutic
segments
added value per unit sold;
geographic expansion; and
growth in key therapeutic
segments
$857
12
Pharmaceutical Packaging Systems
Packaging Components for Small Volume Parenterals
Packaging Components for Small Volume Parenterals
Plungers, Tip caps,
Needle shields for Glass
Syringes
Needle shields for Glass
Syringes
Plungers, lined seals
for Glass Cartridges
for Pens
for Glass Cartridges
for Pens
Primary packaging components (those that touch the drug) are typically
proprietary to West and are “designed into” customers’ drug products
proprietary to West and are “designed into” customers’ drug products
13
Providing Solutions to a Changing Market
14
Faster Growth of High-Value Products
Pharmaceutical Packaging Systems
Pharmaceutical Packaging Systems
15
Asia-Pacific Region Operations
Strategy
Strategy
Singapore
1.High-value Product
Focus
Focus
2.A-P market & special
items
items
3.R&D hub & technical
center
center
China IV Plastic
Global supply
China Elastomer:
China Market,
Efficiency focus
Efficiency focus
India Elastomers for:
1.Domestic standard
products & local support
for multi-nationals
products & local support
for multi-nationals
2.Standard product for
export
export
16
Delivery Systems Segment Overview
$337
• Contract manufacturing base
• Customer owned IP
• Project management
• Automated assembly
• Regulated products
• Proprietary Product
Development
Development
2011 Revenue
($ millions)
17
Acquisition of
Medimop:
Administration
Systems
Medimop:
Administration
Systems
2005
Licensing of
NovaGuard™:
Safety
System
NovaGuard™:
Safety
System
2006
Acquisition of
PharmaPen:
Auto-injector
PharmaPen:
Auto-injector
2007
Daikyo CZ
Insert
Needle
License:
Prefillable
Syringe
Systems
Insert
Needle
License:
Prefillable
Syringe
Systems
2008
Acquisition
of Plastef:
Prefillable
Syringe
Safety
of Plastef:
Prefillable
Syringe
Safety
2009
Acquisition
of LaModel:
Electronic
Patch
Injector
of LaModel:
Electronic
Patch
Injector
2010
Marketing
agreement
agreement
Product
Development
Development
Formation of
PDS division
PDS division
Portfolio Expansion to Meet Market Needs
Acquisition
of B.safe:
Prefilled
syringe
safety
of B.safe:
Prefilled
syringe
safety
2011
18
Pharma Industry Drug Life-Cycle
Management
Management
Phase I
Phase II
Phase III
Post-Market Life Cycle Management
8 - 10 years
2 - 3 years
2 - 3 years
Regulatory
Approval
Discovery
19
Tungsten residue
Breakage
Silicone oil
variability
variability
Cosmetic defects
Particles
Potential Glass Syringe Risk Areas
20
Action Associated with Breakage Issue | Associated Costs | Estimated Cost* |
Investigation and inspection of issues, complaints and syringe products | · Field complaints inquiry · Investigation and resources · Inspection | > $50 Million |
Loss of market share | Loss of sales until re-launch, and loss of 5% of share at market price post re- launch for year 1 | > $50 Million |
Replacement of drug product, components and delivery system after re-launch | 2 million units at $100 each | > $200 Million |
Pipeline Assessment: Drugs in Phase II/III clinical trials | 200,000 units x approx. $100 each cost (assuming 1/10 total production) | >$20 Million |
Significant impacts on product supply, market confidence, brand value | Not estimable | |
* Source: Company estimates
Illustrative Estimates of Recall Costs
21
Daikyo CZ Solution
with Daikyo Flurotec® Barrier Film
with Daikyo Flurotec® Barrier Film
• Reduces:
– drug exposure to extractables
– risk of protein aggregation caused by silicone oil in the drug product
– returns and in-process clean-ups caused by broken glass
– risk of delamination and glass-particulate contamination
• Consistent piston release and travel forces without using silicone oil
Flurotec® is a registered trademark of Daikyo Seiko, Ltd.
22
Orange color indicates Flurotec® film coverage
Complete coverage with
inert film on drug
contact surfaces
inert film on drug
contact surfaces
Flurotec Film
• Patent Protection from Daikyo Seiko
• Trade Secret Molding / Processing
• Silicone-Free System
Daikyo Crystal Zenith Syringe Barrel
• Custom Formulated Resin exclusive
to Daikyo Seiko
to Daikyo Seiko
• IP Filed on CZ 1ml-IN Process
• Other IP on packaging / designs
Daikyo Crystal Zenith Competitive Advantage
Fully laminated
piston
piston
Inside-laminated
tip cap
tip cap
Products Approved in Daikyo Crystal Zenith
hyaluronic acid
MRI contrast
media
media
bone cement
6 Contrast Media
5 MRI
2 Hyaluronic Acid
1 Calcitonin
1 Proton Pump
Inhibitor
Inhibitor
fluconazole
oncology
anticoagulant
2 oncology
1 acyclovir
hyaluronic acid
3 oncology
API Container
Japan
MHLW
Europe
EMEA
US
FDA
Calcitonin
Bone
cement
Zometa
Hyaluronic
acid
24
SmartDose®
Electronic Patch Injector Technology Platform
Programmed by PDA or PC
Dose may be customized
Applied and activated by patient
• Controlled, subcutaneous, micro-infusion delivery
of high volumes and high viscosity drugs
of high volumes and high viscosity drugs
• Prefilled cartridge, no need for user filling
• Based on Daikyo CZ cartridge
• Compact
• Hidden needle for safety
• Single push-button operation
Prototype Operation
25
Revenue per-unit
Consumer product
manufacturing
manufacturing
Medical
device
manufacturing
device
manufacturing
Mix2Vial®
CZ vials
CZ Syringes
Effect of Increasing Proprietary Device Sales
Contract Manufacturing Proprietary Devices
Products
Auto-injector platform
technology
technology
Electronic patch
injector technology
injector technology
26
Our Long-Term Focus
• Pharmaceutical Packaging Systems
– Organic growth of 3-5% per year
– Margin expansion from efficiency, product mix
– Capital investments target enhanced quality and value
• Pharmaceutical Delivery Systems
– Deliver the potential of Daikyo CZ products
– Stronger mix of healthcare-consumable contract manufacturing
– Grow proprietary safety and delivery systems
• Financial discipline
– Operating cash flow supports R&D and capital spending
– Deliver returns (ROIC) that regularly exceed cost of capital (WACC)
– Maintain quarterly dividend
– Align incentives with financial performance and value creation
27
Pharmaceutical Packaging Systems
Pharmaceutical Delivery Systems
• Strong first half
• Established market leader
• Stability with growth potential
• New products well positioned to
meet future market needs
meet future market needs
• The financial strength to invest
Summary
28
Non-GAAP Financial Measures(3)
Three Months Ended March 31, 2012 and 2011
Three Months Ended March 31, 2012 and 2011
(in millions, except per share data)
(3) See “Notes to Non-GAAP Financial Measures” (Slides 31-32), “Cautionary Statement” (Slide 2) for an explanation and
reconciliation of these items.
reconciliation of these items.
As Reported March 31, 2012 | Restructuring and related charges | Acquisition- related contingencies | Discrete tax items | Non-GAAP March 31, 2012 | |
Operating profit | $41.7 | $0.4 | $0.2 | $- | $42.3 |
Interest expense, net | 3.9 | - | - | - | 3.9 |
Income before income taxes | 37.8 | 0.4 | 0.2 | - | 38.4 |
Income tax expense | 9.8 | 0.1 | 0.1 | (0.3) | 9.7 |
Equity in net income of affiliated companies | 1.2 | - | - | - | 1.2 |
Net income | $29.2 | $0.3 | $0.1 | $0.3 | $29.9 |
Net income per diluted share | $0.81 | $0.01 | $- | $0.01 | $0.83 |
As Reported March 31, 2011 | Restructuring and related charges | Discrete tax items | Non-GAAP March 31, 2011 | |
Operating profit | $28.8 | $1.9 | $- | $30.7 |
Interest expense, net | 4.5 | - | - | 4.5 |
Income before income taxes | 24.3 | 1.9 | - | 26.2 |
Income tax expense | 6.1 | 0.6 | (0.2) | 6.5 |
Equity in net income of affiliated companies | 1.4 | - | - | 1.4 |
Net income | $19.6 | $1.3 | $0.2 | $21.1 |
Net income per diluted share | $0.56 | $0.04 | $- | $0.60 |
29
30
Non-GAAP Financial Measures(1)
Three Months Ended June 30, 2012 and 2011
Three Months Ended June 30, 2012 and 2011
(in millions, except per share data)
(1) See “Notes to Non-GAAP Financial Measures” (Slides 31-32) and “Cautionary Statement” (Slide 2) for an explanation and reconciliation of these
items.
items.
As Reported June 30, 2012 | Restructuring, impairment & related charges | Acquisition- related contingencies | Extinguishment of debt | Non-GAAP June 30, 2012 | |
Operating profit | $35.6 | $3.7 | $0.2 | $- | $39.5 |
Loss on debt extinguishment | 11.6 | - | - | 11.6 | - |
Interest expense, net | 4.0 | - | - | - | 4.0 |
Income before income taxes | 20.0 | 3.7 | 0.2 | 11.6 | 35.5 |
Income tax expense | 6.5 | 1.4 | - | 1.8 | 9.7 |
Equity in net income of affiliated companies | 2.1 | - | - | - | 2.1 |
Net income | $15.6 | $2.3 | $0.2 | $9.8 | $27.9 |
Net income per diluted share | $0.45 | $0.06 | $0.01 | $0.27 | $0.79 |
As Reported June 30, 2011 | Restructuring, impairment & related charges | Acquisition- related contingencies | Special separation benefits | Non-GAAP June 30, 2011 | |
Operating profit | $27.8 | $1.3 | ($0.7) | $2.1 | $30.5 |
Interest expense, net | 4.3 | - | - | - | 4.3 |
Income before income taxes | 23.5 | 1.3 | (0.7) | 2.1 | 26.2 |
Income tax expense | 5.3 | 0.4 | (0.1) | 0.8 | 6.4 |
Equity in net income of affiliated companies | 1.9 | - | - | - | 1.9 |
Net income | $20.1 | $0.9 | ($0.6) | $1.3 | $21.7 |
Net income per diluted share | $0.57 | $0.02 | ($0.01) | $0.04 | $0.62 |
31
NOTES TO NON-GAAP FINANCIAL MEASURES
For additional details, please see today’s press release and Safe Harbor Statement.
For additional details, please see today’s press release and Safe Harbor Statement.
(continued on following slide)
These presentation materials and associated presentation use the following financial measures that have not been calculated in accordance with
generally accepted accounting principles (GAAP) accepted in the U.S., and therefore are referred to as non-GAAP financial measures:
generally accepted accounting principles (GAAP) accepted in the U.S., and therefore are referred to as non-GAAP financial measures:
·Adjusted operating profit
·Adjusted net income
·Adjusted diluted EPS
·Net debt
·Net debt to total invested capital
West believes that these non-GAAP measures of financial results provide useful information to management and investors regarding business
trends, results of operations, and the Company’s overall performance and financial position. Our executive management team uses these
financial measures to evaluate the performance of the Company in terms of profitability and efficiency, to compare operating results to prior
periods, to evaluate changes in the operating results of each segment, and to measure and allocate financial resources to our segments. The
Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing
operating results and trends in comparing its financial measures with other companies.
trends, results of operations, and the Company’s overall performance and financial position. Our executive management team uses these
financial measures to evaluate the performance of the Company in terms of profitability and efficiency, to compare operating results to prior
periods, to evaluate changes in the operating results of each segment, and to measure and allocate financial resources to our segments. The
Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing
operating results and trends in comparing its financial measures with other companies.
Our executive management does not consider such non-GAAP measures in isolation or as an alternative to such measures determined in
accordance with GAAP. The principal limitation of these financial measures is that they exclude significant expenses and income that are
required by GAAP to be recorded. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management
about which items are excluded. In order to compensate for these limitations, non-GAAP financial measures are presented in connection with
GAAP results. We urge investors and potential investors to review the reconciliations of our non-GAAP financial measures to the comparable
GAAP financial measures, and not to rely on any single financial measure to evaluate the Company’s business.
accordance with GAAP. The principal limitation of these financial measures is that they exclude significant expenses and income that are
required by GAAP to be recorded. In addition, they are subject to inherent limitations as they reflect the exercise of judgment by management
about which items are excluded. In order to compensate for these limitations, non-GAAP financial measures are presented in connection with
GAAP results. We urge investors and potential investors to review the reconciliations of our non-GAAP financial measures to the comparable
GAAP financial measures, and not to rely on any single financial measure to evaluate the Company’s business.
In calculating adjusted operating profit, adjusted net income and adjusted diluted EPS, we exclude the impact of items that are not considered
representative of ongoing operations. Such items include restructuring and related costs, certain asset impairments, other specifically identified
gains or losses, and discrete income tax items. A reconciliation of these adjusted non-GAAP measures to the comparable GAAP financial
measures is included in the accompanying tables.
representative of ongoing operations. Such items include restructuring and related costs, certain asset impairments, other specifically identified
gains or losses, and discrete income tax items. A reconciliation of these adjusted non-GAAP measures to the comparable GAAP financial
measures is included in the accompanying tables.
The following is a description of the items excluded from adjusted operating profit, adjusted net income and adjusted diluted EPS for the three
- and six-month periods presented in the accompanying tables:
- and six-month periods presented in the accompanying tables:
Restructuring, impairment & related charges - During the three months ended June 30, 2012, we incurred restructuring, impairment and
related charges of $3.7 million, the majority of which related to impairment charges of $3.4 million, as we concluded that the estimated fair
related charges of $3.7 million, the majority of which related to impairment charges of $3.4 million, as we concluded that the estimated fair
32
NOTES TO NON-GAAP FINANCIAL MEASURES
For additional details, please see today’s press release and Safe Harbor Statement.
For additional details, please see today’s press release and Safe Harbor Statement.
value of one of our product lines no longer exceeded the carrying value of the related assembly equipment and intangible asset. The
remaining charges were restructuring and related charges associated with the restructuring plan announced in December 2010, primarily for
employee severance and benefits, as well as asset transfer and facility closure costs.
remaining charges were restructuring and related charges associated with the restructuring plan announced in December 2010, primarily for
employee severance and benefits, as well as asset transfer and facility closure costs.
Acquisition-related contingencies - During the three months ended June 30, 2012, we increased the liability for contingent consideration
related to our 2010 acquisition of technology used in our SmartDose™ electronic patch injector system by $0.2 million, due to accretion
expense. During the three months ended June 30, 2011, we eliminated $0.8 million of contingent consideration related to our July 2009 éris
safety syringe system acquisition. This reflected our assessment that none of the contractual operating targets will be achieved over the earn-
out period, which ends in 2014. Partially offsetting this reduction was accretion expense related to the SmartDose electronic patch injector
technology acquisition.
related to our 2010 acquisition of technology used in our SmartDose™ electronic patch injector system by $0.2 million, due to accretion
expense. During the three months ended June 30, 2011, we eliminated $0.8 million of contingent consideration related to our July 2009 éris
safety syringe system acquisition. This reflected our assessment that none of the contractual operating targets will be achieved over the earn-
out period, which ends in 2014. Partially offsetting this reduction was accretion expense related to the SmartDose electronic patch injector
technology acquisition.
Extinguishment of debt - During the three months ended June 30, 2012, we recognized a loss on debt extinguishment of $11.6 million
related to our repurchase of $158.4 million in aggregate principal amount of 4.00% Convertible Junior Subordinated Debentures Due 2047,
which included the purchase premium, transaction costs and a non-cash charge for unamortized debt issuance costs of the purchased
Convertible Debentures. The purchase of the Convertible Debentures results in a 2.9 million share, or 7.8%, prospective reduction in West
common shares included in the measurement of diluted earnings per share. Excluding the loss on debt extinguishment recognized in the
current quarter, the effect is expected to be accretive to earnings per diluted share going forward, after accounting for interest expense to be
incurred in connection with notes issued on July 5, 2012, the proceeds of which provided the permanent financing for the purchase of the
Convertible Debentures.
related to our repurchase of $158.4 million in aggregate principal amount of 4.00% Convertible Junior Subordinated Debentures Due 2047,
which included the purchase premium, transaction costs and a non-cash charge for unamortized debt issuance costs of the purchased
Convertible Debentures. The purchase of the Convertible Debentures results in a 2.9 million share, or 7.8%, prospective reduction in West
common shares included in the measurement of diluted earnings per share. Excluding the loss on debt extinguishment recognized in the
current quarter, the effect is expected to be accretive to earnings per diluted share going forward, after accounting for interest expense to be
incurred in connection with notes issued on July 5, 2012, the proceeds of which provided the permanent financing for the purchase of the
Convertible Debentures.
Special separation benefits - During the three months ended June 30, 2011, we incurred $2.1 million in special separation benefits related to
the retirement of our former President and Chief Operating Officer. These costs were primarily for the revaluation and acceleration of stock-
based compensation expense as a result of amendments to equity awards that allow certain of his awards to continue to vest over the original
vesting period instead of being forfeited upon separation.
the retirement of our former President and Chief Operating Officer. These costs were primarily for the revaluation and acceleration of stock-
based compensation expense as a result of amendments to equity awards that allow certain of his awards to continue to vest over the original
vesting period instead of being forfeited upon separation.
WEST PHARMACEUTICAL SERVICES, INC.
Solutions for Injectable Drug Delivery NYSE:WST www.westpharma.com
© 2012 by West Pharmaceutical Services, Inc., Lionville, PA.
All rights reserved. This material is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any
form or by any means, electronic, mechanical, photocopying or otherwise, without written permission of West Pharmaceutical Services, Inc.. All
trademarks and registered trademarks are property of West Pharmaceutical Services, Inc., unless noted otherwise.
form or by any means, electronic, mechanical, photocopying or otherwise, without written permission of West Pharmaceutical Services, Inc.. All
trademarks and registered trademarks are property of West Pharmaceutical Services, Inc., unless noted otherwise.